Abstract:Background Conventional corticosteroid therapy after laser epithelial keratomileusis (LASEK) is topical application of 0.1％ fluorometholone eye drops for 4 months,but this therapy increases the ocular hypertension risk and leads to poor compliance in patients.It is necessary to explore a safe and effective brachytherapeutic drug.Objective This study was to compare the clinical outcomes between the brachytherapy of 0.5％ loteprednol etabonate eye drops and the long-term therapy of 0.1％ fluorometholone eye drops after LASEK.Methods Clinical data were retrospectively analyzed from 208 right eyes in 208 mild and moderate myopia patients who received LASEK at Peking University Third Hospital from 2009 to 2013.The eye drops of 0.5％ loteprednol etabonate was used 6 times daily since operation day until postoperative day 5,and 4 times daily for a week,and then tapered for three consecutive weeks in 104 eyes of the loteprednol group after LASEK,and 0.1％ fluorometholone eye drops was applied topically 4 times daily for initial one month and then tapered for three consecutive months in another 104 eyes in the fluorometholone group after LASEK.Corneal epithelial healing time was compared between the two groups by recording the wearing duration of corneal contact lens.Noncontact intraocular pressure (lOP) was detected and corrected 5 days,2 weeks,1 month and 3,6 months after LASEK.Haze was scored based on the criteria of Cheng under the slit lamp microscope and apparently optometry was performed 1 month and 3,6 months after LASEK.Results The number of eyes removed corneal contact lens in 5,6 and 7 days after LASEK was not significantly different between the loteprednol group and the fluorometholone group (x2 =1.180,P =0.554).No considerable differences were seen in the eye numbers with the equivalent spherical lens (absolute value) ≤0.5 D in 1 month,3months and 6 months after LASEK (Z=-1.028,P=0.304;Z=-0.398,P=0.691;Z=-0.445,P=0.656).In the fifth days after surgery,the median corrected IOP was 13.52 mmHg and 13.12 mmHg in the loteprednol group and the fluorometholone group,respectively,showing a significant difference between them (Z =-1.985,P =0.047),but no significant differences were found in IOP in 2 weeks,1 month and 3 months,6 months after surgery between the two groups (all at P＞0.05).IOP elevated (postoperative IOP-preoperative IOP ≥ 5 mmHg) after LASEK in 5 eyes in the loteprednol group and 4 eyes in the fluorometholone group (x2 =0.116,P =0.733).In 1 month after surgery,the number of eyes in different grades of haze was significantly decreased in the loteprednol group compared with the fluorometholone group (x2=13.506,P=0.009),however,there was no significant differences in haze grading in postoperative 3 months and 6 months between the two groups (x2 =2.199,P =0.699;x2 =1.154,P =0.562).Conclusions Brachytherapy of 0.5％ loteprednol etabonate eye drops appears to have a similar effect in antiinflammation and inhibition of haze to the long-term therapy of 0.1％ fluorometholone eye drops after LASEK.Furthermore,topical application of 0.5％ loteprednol etabonate eye drops dose not increase the risk of ocular hypertension.

Clinical observation on the application of 5g/L loteprednol etabonate ophthalmic suspension after LASIK

A Randomized-Controlled Clinical Trial on the Application of 0.5％ Ioteprednol Etabonate Eye Drops after Myopic Laser-Assisted in Situ Keratomileusis Surgery

Clinical Comparison Between Brachytherapy of 0.5 ％ Loteprednol Etabonate Eye Drops and Long-Term Therapy of 0.1％ Fluorometholone Eye Drops after LASEK

Clinical study on the effects of loteprednoletabonate 0.5％/Tobramycin 0.3％ eyedrops after lamellar corneal refractive surgery

Changes of dry eye parameters after femtosecond laser and conventional LASIK

[Study on the treatment of dry eye with Loteprednol Etabonate]

The Pharmaceutical Prevetion of Diffuse Lamellar Keratitis after LASIK

Clinical observation of partial using of 0.1％ bromfenac sodium after laser-assisted subepithelial keratomileusis in low and medium myopia

Efficacy and Safety of Loteprednol Etabonate Versus Fluorometholone in the Treatment of Patients after Corneal Refractive Surgery: a Meta-Analysis

Efficacy Observation of 0.1％ Bromfenac Sodium Eye Drops on Relieving the Post-Lasek Irritative Symptoms

Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis

A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.

Treatment Effects of 0.5% Timolol on Refractive Regression in Eyes after Laser in Situ Keratomileusis

The effect of different potency glucocorticosteroids treatments on tear inflammatory factors and corneal optical density after femtosecond-assisted laser in situ keratomileusis

Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery

Clinical Observation of Silicone Hydrogel Contact Lenses Applied Immediately after Laser in Situ Keratomileusis

Deproteinized calf blood extract gel and hydroxyl-glucoside eye drops on recovery of corneal epithelial injury after LASIK

Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery

A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance

Clinical Assessment of Proanoprefen Eyedrops on Postoperative Inflammation from LASEK

Clinical Study of Diffuse Lamellar Keratitis after Laser in Situ Keratomileusis